Oncolytic Adenoviral Therapy Plus Pembrolizumab in BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Phase 2 CORE-001 Trial
January 07, 2025
Video
STATE-OF-THE-INDUSTRY VIDEO BY LEADING UROLOGY EXPERTS
CORE-001 Study: Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab
Roger Li, MD & Trinity Bivalacqua, MD, PhD
Roger Li and Trinity Bivalacqua join Ashish Kamat in a discussion on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CG Oncology, Inc. today announced the publication in Nature Medicine of final results from the Company’s CORE-001 Phase 2 trial of cretostimogene plus pembrolizumab in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NIMBC).
Oncolytic Adenoviral Therapy Plus Pembrolizumab in BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Phase 2 CORE-001 Trial
Li, R., Shah, P.H., Stewart, T.F. et al.
Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette–Guérin (BCG)-experienced non-muscle-invasive bladder cancer.
Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Roger Li, MD
The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on bladder cancer, and a presentation by Dr. Roger Li discussing the final results of CORE-001, a phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with CIS.
